ARCHWAY Randomized Phase 3 Trial of the Port Delivery System With Ranibizumab for Neovascular Age-related Macular Degeneration
| Overview / Abstract: |
January 2022: VBS Literature Update Holekamp NM, Campochiaro PA, Chang M, et al, on behalf of all Archway Investigators. ARCHWAY randomized phase 3 trial of the port delivery system with ranibizumab for neovascular age-related macular degeneration. Ophthalmology. 2021. doi: https://doi.org/10.1016/j.ophtha.2021.09.016. Abstract by Nika Bagheri, MD |
|
Expiration |
Jan 31, 2023 |
|
Discipline(s) |
Optometry / Ophthalmology CE |
|
Format |
Journal, Online |
|
Credits / Hours |
0.5 |
|
Accreditation |
ACCME |
|
Keywords / Search Terms |
Evolve Medical Education LLC Free CE CME |
|